East African Medical Journal 1998-Nov
Human plasma derived hepatitis B vaccine: Kenyan experience.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
O link é salvo na área de transferência
Palavras-chave
Resumo
OBJECTIVE
To determine the efficacy and safety of hepaccine B.
METHODS
Vaccination on first-come-first-served basis.
METHODS
Kenya Medical Research Institute (KEMRI) staff and families at Nairobi, Kenya.
METHODS
A total of 107 vaccinees aged 0-10 years and 10 years and above.
RESULTS
Antibody to hepatitis B surface antigen (anti HBs) checked one month after the third dose of the vaccine.
RESULTS
Ninety seven per cent of the vaccinees developed antiHBs. Side effects were few in the form of soreness at site of injection and headache.
CONCLUSIONS
Hepaccine B produced good immune response in vaccinees with minimal side effects.
